Halozyme Therapeutics
ISIN US40637H1095
|WKN A0DLHS
Overview
Description
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 6,560.99 m |
| EPS, EUR | 3.17 |
| P/B ratio | 20.38 |
| P/E ratio | 17.55 |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 938.64 m |
| Net income, EUR | 410.55 m |
| Profit margin | 43.74% |
What ETF is Halozyme Therapeutics in?
There are 33 ETFs which contain Halozyme Therapeutics. All of these ETFs are listed in the table below. The ETF with the largest weighting of Halozyme Therapeutics is the First Trust NYSE Arca Biotechnology UCITS ETF Acc.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
